Mumbai, May 14 -- EBITDA jumped 42% year-on-year (YoY) to Rs 425 crore in Q4FY25. EBITDA margin improved to 25% in Q4 FY25, compared to 20% in Q4 FY24. Profit before tax rose 108% YoY to Rs 228 crore in Q4FY25.

For the full year, net profit rose 57% to Rs 88 crore on 32% increase in revenue from operations to Rs 580 crore in the year ended March 2025 over the year ended March 2024. EBITDA rose 30% YoY to Rs 161 crore in FY25. EBITDA margin was unchaged at 28% in FY25. PBT climbed 56% YoY to Rs 119 crore in FY25.

Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said, "We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our ...